Connect with us

Hi, what are you looking for?

press release

Ampio Pharmaceuticals (AMEX:AMPE) – Moore Kuehn, PLLC encouraged – Press Release

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) — Moore Kuehn, PLLC, a Wall Street-based securities law firm, is investigating whether certain officers and directors of Ampio Pharmaceuticals, Inc. AMPE breached their fiduciary duties to shareholders.

Pursuant to a state securities lawsuit, Ampio Pharmaceuticals insiders caused the company to make false and/or misleading statements and/or failed to disclose the following: (i) inflated the company’s true ability to successfully file a BLA for Ampion; (ii) the results of the AP-013 study and the timing of unblinding the data from the AP-013 study were overstated; and (iii) that as a result of the foregoing, statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis.

If you own AMPE please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or by calling (212) 709-8245. You will not incur any costs. Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers. please visit http://www.moorekuehn.com/practice/new-york-shareholder-derivative-litigation/

attorney advertising. Previous results do not guarantee similar results.

Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th floor
New York, New York 10005
jkuehn@moorekuehn.com
(212) 709-8245


Source Story here

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...